Switching from dupilumab to tralokinumab in patients with atopic dermatitis due to inefficacy or side effects. Lasheras-Perez MA, Palacios-Diaz RD, Pozuelo-Ruiz M, Torres-Navarro I, et al. Int J Dermatol 2023 Nov 28. doi: 10.1111/ijd.16926.

Read + Share

Amedeo Smart

Independent Medical Education

Lasheras-Perez MA, Palacios-Diaz RD, Pozuelo-Ruiz M, Torres-Navarro I, et al. Switching from dupilumab to tralokinumab in patients with atopic dermatitis due to inefficacy or side effects. Int J Dermatol 2023 Nov 28. doi: 10.1111/ijd.16926.
PMID: 38014601